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a  b  s  t  r  a  c  t
Introduction:  In  2011,  two  years  after  the introduction  of  7-valent  Pneumococcal  conjugate  vaccine
(PCV7),  the Gambian  immunization  programme  replaced  PVC7  with  PCV13  (13-valent).  Our  objective
was  to assess  the  additional  impact  of PCV13  on  prevalence  of  pneumococcal  nasopharyngeal  carriage.
Methods:  We  recruited  healthy  Gambian  infants  who  had  received  three  PCV  doses.  Nasopharyngeal
swabs  were  collected  from  infants  and  their  mothers  during  two  cross-sectional  surveys  (CSS) conducted
in  infants  vaccinated  with  PCV7  (CSS1)  and vaccinated  with  PCV13  (CSS2).  Pneumococci  were  isolated  and
serotyped following  standardized  methods.  Whole  genome  sequencing  was  performed  on  non-typable
pneumococcus  isolated  in  CSS1  and  CSS2.
Results: 339  and  350  infants  and  their  mothers  were  recruited  in  CSS1  and  CSS2,  respectively.  Overall
prevalence  of  pneumococcal  carriage  was  85.4%  in  infants.  Among  infants,  prevalence  of vaccine  type
(VT) carriage  was  lower  in  CSS2  [9.4%  versus  4.9%  (p  =  0.025)  for  PCV7-VT;  33.3%  versus  18.3% (p  <  0.001)
for  PCV13-VT  and  23.9%  versus  13.7%  (p  = 0.001)  for the 6 additional  serotypes  included  in  PCV13].  At
CSS2,  there  was  a decrease  of serotypes  6A  (from  15.3%  to  5.7%,  p < 0.001)  and  19F  (from  5.6%  to 1.7%,
p  =  0.007),  and  an  increase  of  non-typable  pneumococci  (0.3–6.0%,  p <  0.001),  most  of which  (82.4%)  were
from  typable  serotype  backgrounds  that  had  lost  the  ability  to express  a capsule.  Prevalence  of  overall
and  VT carriage  in  mothers  was similar  in  CSS1  and  CSS2.
Conclusions:  Replacing  PCV7  for PCV13  rapidly  decreased  prevalence  of  VT carriage  among  vaccinated
Gambian  infants.  An indirect  effect  in  mothers  was  not  observed  yet.  Vaccine-driven  selection  pressure
may  have  been  responsible  for the  increase  of  non-typable  isolates.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
∗ Corresponding author at: PO Box 273, Medical Research Council Unit, The
Gambia.
E-mail address: aroca@mrc.gm (A. Roca).
1. Background
Prevention of pneumococcal disease is a major, international
public health priority due to the high burden of disease and asso-
ciated mortality, especially in children in developing countries
[1]. Pneumococcal conjugate vaccines (PCVs) prevent pneumo-
coccal disease by reducing the carriage of serotypes included in
the vaccine [2,3]. PCVs are currently used in routine childhood
http://dx.doi.org/10.1016/j.vaccine.2015.11.012
0264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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vaccination programmes in many developed and developing
countries. Because children are the main drivers of transmission [4],
vaccinating children also protects older members of the community
from both nasopharyngeal carriage and invasive disease [2,5–9].
Some studies undertaken after the introduction of PCVs have shown
an increase in both the incidence of invasive pneumococcal dis-
ease and in the prevalence of carriage caused by pneumococcal
serotypes not included in the vaccine (non-vaccine-serotypes or
NVT), [2,3,8,10–13]. This replacement of VT serotypes with NVT
serotypes has also been observed in non-vaccinated older members
of vaccinated communities [14]. However, the capsule is a determi-
nant of virulence, and VT serotypes tend to be more virulent than
NVT [15]. Consequently, there has been an overall reduction in inva-
sive pneumococcal disease since the introduction of pneumococcal
vaccination, despite serotype replacement [8].
Because conjugate vaccines target the pneumococcal capsule,
pneumococci can evade vaccine-induced immunity by changing
their serotype, or losing their capsule altogether, through genetic
recombination, described as switching [16,17].
The ﬁrst licensed PCV vaccine included 7 out of the more than
90 pneumococcal serotypes. This vaccine did not include the most
prevalent serotypes causing disease in Africa and other developing
regions. To address this challenge, PCV13 was licensed based on
safety and immunogenicity data in comparison with PCV7. PCV13
contains 13 capsular pneumococcal polysaccharides that are indi-
vidually conjugated to non-toxic diphtheria protein. In addition to
the 7 serotypes in PCV7 (4, 6B, 9V, 14,18C, 19F and 23F), PCV13
contains serotypes 1, 3, 5, 6A, 7F and 19A. Together these are the
13 most common serotypes causing invasive pneumococcal dis-
ease globally [18]. The impact of PCVs on nasopharyngeal carriage
is considered a predictor of vaccine effectiveness [19] and carriage
studies can be used to predict the potential impact of different for-
mulations of PCVs on VT among the vaccinated population (direct
effect) and other age groups (indirect effect). A vaccine trial con-
ducted in Israel, which compared the efﬁcacy of PCV13 versus PCV7,
showed a reduction in the acquisition and prevalence of nasopha-
ryngeal colonization for the additional serotypes included in PCV13
as well as a lower prevalence of serotypes 6C and 19F [20]. The
objective of this study was to compare the effectiveness of three
doses of PCV13 with that of three doses of PCV7 in preventing
pneumococcal nasopharyngeal colonization among infants in The
Gambia and to assess the indirect effect of this formulation on
their mothers. In addition, we analyzed the molecular basis for the
observed increase in the prevalence of non-typable pneumococcus
after PCV13 vaccination.
2. Materials and methods
2.1. Pneumococcal conjugate vaccination in The Gambia
The Gambia was the second country in Africa to introduce PCV7
as part of its Expanded Programme of Immunization (EPI), starting
in the second half of 2009 and following three-dose schedule with
vaccine given at the age of 2, 3 and 4 months of age. Although there
was no formal catch-up campaign, most of children under 2 years
of age received one dose of PCV7 soon after its introduction. In
June 2011, PCV7 was replaced by PCV13 in the EPI programme. EPI
coverage in the country is >90% for DPT3 and a similar coverage is
expected for PCVs [21].
2.2. Study population
The study was conducted in a peri-urban area situated on the
western margin of The Gambia, approximately 20 km from the cap-
ital Banjul. The population of the study area is ethnically mixed,
and engaged in a wide range of occupations, including working for
government services, some professions and trading. The climate of
the area is typical of the sub-Sahel with a long dry season from
November to May.
The study was  carried out at two health centres, Sukuta Health
Centre and Jammeh Foundation for Peace. These are government
run health centres and vaccination clinics located approximately
8 km from Fajara where the main laboratories at the Medical
Research Council (MRC) are based. Children and their mothers were
identiﬁed and recruited in the vaccination clinics of the health cen-
tres. These health centres serve a local community of more than
25,000 inhabitants each, with an overall annual birth cohort of more
than 7000 children.
2.3. Study design and samples
We conducted a study of pneumococcal nasopharyngeal car-
riage before and after the introduction of PCV13. The ﬁrst
cross-section survey (CSS1) was conducted between March and
June 2011 among children who had received three doses of PCV7.
The second survey (CSS2) was  conducted following the introduc-
tion of PCV13 between March and June 2012 among children who
had received three doses of PCV13.
Infants 6–11 months of age were recruited at EPI vaccine clin-
ics. To be eligible for the study, children had to be healthy, to have
received three documented doses of PCV (PCV7 in CSS1 or PCV13
in CSS2) with the third dose received at least 4 weeks before enter-
ing the survey. If consent was  given, a nasopharyngeal swab (NPS)
was taken from the infant and their mother. Demographic data and
data on risk factors for carriage were obtained by interviewing the
mother using a structured questionnaire.
The study was approved by the joint MRC/Gambia Government
Ethics Committee and by the ethics committee of the London School
of Hygiene and Tropical Medicine.
2.4. NPS collection
NPSs were collected from the posterior wall of the nasopha-
rynx using an alginate swab and immediately inoculated into vials
containing skim milk–tryptone–glucose–glycerol (STGG) transport
medium, which was  placed in a cold box before transfer to the Med-
ical Research Council Laboratories at Fajara within 8 h of collection,
in accordance with the WHO  protocol for evaluation of pneumococ-
cal carriage [22]. Inoculated vials were stored at −70 ◦C until tested
in batches.
2.4.1. Microbiological methods
Frozen STGG containing nasopharyngeal swabs were initially
thawed on ice and then vortexed brieﬂy for a minimum of 20 s.
200 l of STGG was transferred into 5 ml  of Todd Hewitt broth
containing 5% yeast extract, and 1 ml  of rabbit serum. The mix-
ture was vortexed brieﬂy before incubating for 4–6 h at 37 ◦C. At
the end of the incubation period, the broth was vortexed again and
50 l aliquot inoculated on to gentamycin blood agar (GBA). The
inoculum was  streaked onto four quadrants in order to semi quan-
titatively determine the bacterial load (from 1 to 4) as described
elsewhere [23]. After 20–24 h incubation at 37 ◦C with 5% CO2, GBA
plates were examined for alpha hemolytic colonies. Presumptive
pneumococcal colonies were then screened for optochin suscepti-
bility.
Pneumococcal isolates were serotyped using the latex agglu-
tination techniques as described previously [24]. All non-typable
isolates were repeated and only considered non-typables when
conﬁrmed by the second test.
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2.5. Sample size calculation
We  chose a sample size of 350 infants per CSS to detect a 40%
reduction in the prevalence of PCV(13-7)-VT (from 24% to 14%),
with 90% power and a type 1 error of 5%.
2.6. Statistical analysis
The overall prevalence of pneumococcal carriage, the preva-
lence of individual serotypes, and the prevalence of VT serotypes
was determined in each survey. The latter were classiﬁed in three
ways: (i) serotypes included in PCV7 (PCV7 VT), (ii) serotypes
included in PCV13 (PCV13 VT), and (iii) serotypes included in PCV13
but not in PCV7 (PCV13-7 VT).
Poisson regression was used to estimate prevalence ratios com-
paring CSS1 and CSS2. For mothers and children the ratios were
adjusted for maternal age, household size, health centre and mater-
nal education. For children the ratios were additionally adjusted for
age and gender, antibiotic use (of the infant) and exposure to smoke
from cooking. p-Values and conﬁdence intervals were calculated
using robust variance estimates.
We  used Fisher’s exact to test the hypothesis that the proportion
of PCV13 VT among non-typables that had lost their capsule was
equal to the proportion in the population as a whole.
All analyses were done using Stata version 13.
Whole genome sequence analysis
Whole genome sequencing (WGS) was conducted among non-
typable pneumococci isolated from mothers and infants in both
study CSSs.
Samples of genomic DNA from study pneumococcal isolates
were sequenced using Illumina HiSeq, 100 bp paired end with
350 bp inserts. Kraken was  used to differentiate between pneumo-
cocci and closely related species and to identify any potential
contamination [25]. MLST was derived from de novo Velvet assem-
blies [26]. Detection of known serotype speciﬁc sequences in
assemblies and mapping against known capsular loci was per-
formed as previously described [27,28].
Sequence reads were mapped against the reference genome for
S. pneumoniae ATCC 700669 [29] using a pipeline developed in-
house at The Sanger Institute that utilizes SMALT (http://www.
sanger.ac.uk/resources/software/smalt/). In addition to the 34 non-
typable genomes sequenced for this study a total of 64 isolates from
independent pneumococcal sequencing projects were included in
the analysis to give serological context to the phylogeny; six classi-
cally non-typable isolates [30], 52 Gambian isolates from a previous
study [31] and a further 6 Gambian isolates from the Global Pneu-
mococcal Sequencing project (http://www.pneumogen.net/gps/).
The resultant alignment was reduced to variable sites and phy-
logeny created using RaxML [32]. Single nucleotide polymorphisms
(SNPs) were reconstructed on the phylogeny using an in-house
accelerated transformation parsimony method rooted on Strep-
tococcus pseudopneumoniae. The phylogeny was visualized and
annotated in ITOL [32]. The data were deposited in the ENA with
accession numbers provided in the supplementary data.
3. Results
3.1. Study proﬁle
Six hundred and eighty-nine infants and their mothers were
recruited and sampled from the study (339 in CSS1 and 350 in CSS2).
Approximately half of the recruited infants were male (50.2%) and
their median age was 8 months. Because 11 children were twins,
only 678 mothers were sampled [median age 25 years]. Sampling
Table 1
Characteristics of the children and their mothers who participated in cross sectional
surveys undertaken before (CSS1) and after (CSS2) the introduction of PCV13 into
the  Gambian EPI programme.
Variable CSS1a (n = 339)
n (%)
CSS2a (n = 350)
n (%)
Health centre
Jammeh Foundation 229 (67.6) 251 (71.7)
Sukuta 110 (32.4) 99 (28.3)
Total 339 350
Gender
Female 159 (46.9) 184 (52.7)
Male 180 (53.1) 165 (47.3)
Total 339 349
Antibiotic useb
No 295 (88.6) 319 (92.2)
Yes 38 (11.4) 27 (7.8)
Total 333 346
Mother’s schooling
None or <1 year 137 (41.8) 110 (31.6)
1-3 years 46 (14.0) 36 (10.3)
4-6 years 80 (24.4) 44 (12.6)
>6 years 65 (19.8) 158 (45.4)
Total 328 348
Mother cooks with child on back
No 226 (66.9) 189 (54.3)
Yes 112 (33.1) 159 (45.7)
Child age (months)
Median (IQR) 8.2 (7.0,9.6) 7.6 (6.7,9.2)
Household size
Median (IQR) 5.0 (4.0,7.0) 3.0 (3.0,5.0)
Mother’s age (years)
Median (IQR) 24.5 (21.0,29.0) 25.0 (21.0,28.0)
a There were 11 pairs of twins (i.e., 22 twins in total), 8 pairs in the PCV-7 survey
and 3 pairs in the PCV-13 survey. The number of mothers was 331 and 347 in CSS1
and CSS2 respectively.
b Within one month before entering the study.
occurred between 24th March and 9th June in 2011 for CSS1; and
27th March and 7th of June 2012 for CSS2. Table 1 provides a sum-
mary of the epidemiological characteristics of individuals included
in each CSS survey.
3.2. Prevalence of pneumococcal carriage pre and post PCV13
introduction
Infants: The overall prevalence of pneumococcal carriage among
infants was  similar in both surveys (85.8% and 84.3%, p = 0.594).
However, the prevalence of VT decreased between CSS1 and CSS2
[from 23.9% to 13.7% (p < 0.001) for PCV(13-7)VT; from 33.3% to
18.3% (p < 0.001) for PCV13-VT; and from 9.4 to 4.9 (p = 0.025)
for PCV7-VT]. The decrease in VT prevalence was mainly due to
a decreasing in serotype 6A (from 15.3% to 5.7% – p < 0.001) and
19F (from 5.6% to 1.7% – p = 0.007). The prevalence of non-typable
serotypes increased in CSS2 (from 0.3% to 6.0% – p < 0.001) (Table 2).
Similar results were found in the crude and adjusted analyses
(Table 2). Apart from the non-typables, there was no signiﬁcant
increase of any NVT.
Mothers: The overall prevalence of pneumococcal carriage
among mothers was  lower than in infants but similar in CSS1
and CSS2 (23.0% versus 24.2%, p = 0.718). For the different study
endpoints, differences between study CSSs were small and did
not reach statistical signiﬁcance in the crude or adjusted analy-
sis (Table 3). The most prevalent serotypes among mothers were
serotype 16 in CSS1 and 19A in CSS2.
3.3. Genotypic analysis of non-typable isolates
WGS  was  performed for all 28 phenotypically non-typable iso-
lates; 22 from the infants (1 in CSS1 and 21 in CSS2) and 6 from
the mothers (1 and 5 in CSS1 and CSS2 respectively). Three (10.7%)
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Table  2
Prevalence of pneumococcal carriage in infants in surveys conducted before (CSS1) and after (CSS2) Introduction of PCV13 ito the Gambian EPI programme.
Prevalence of carriage RR p-Valuea RRadjb p-Value
CSS1 (N = 339) CSS2 (N = 350)
Vaccine groups
PCV13-VT 33.3 18.3 0.55 (0.42,0.72) <0.001 0.52 (0.39,0.69) <0.001
PCV7-VT 9.4 4.9 0.51 (0.29,0.91) 0.025 0.52 (0.28,0.97) 0.039
PCV(13-7)-VT 23.9 13.7 0.57 (0.41,0.79) 0.001 0.53 (0.38,0.74) <0.001
Pneumococcus 85.8 84.3 0.98 (0.92,1.05) 0.594 1.00 (0.93,1.07) 0.897
PCV13-VT
1  0 0 NA NA NA NA
3  0 0.3 NA 1.000 NA NA
4  0.6 0 NA 0.242 NA NA
5  0.3 1.4 4.84 (0.57,41.30) 0.217 4.59 (0.55,38.43) 0.160
6A  15.3 5.7 0.37 (0.23,0.61) <0.001 0.35 (0.21,0.59) <0.001
6B  0.9 0 NA 0.119 NA NA
7F  0 0 NA NA NA NA
9V  0 0 NA NA NA NA
14  0.6 0.9 1.45 (0.24,8.65) 1.000 2.12 (0.36,12.35) 0.403
18C  0.6 0 NA 0.242 NA NA
19A  8.3 6.3 0.76 (0.44,1.30) 0.379 0.66 (0.39,1.10) 0.112
19F  5.6 1.7 0.31 (0.12,0.76) 0.007 0.29 (0.10,0.78) 0.015
23F  1.5 2.3 1.55 (0.51,4.69) 0.578 1.51 (0.49,4.64) 0.468
NVT
10A  4.7 4 0.85 (0.42,1.71) 0.711 0.89 (0.41,1.93) 0.761
13  3.5 3.4 0.97 (0.44,2.13) 1.000 1.06 (0.45,2.52) 0.892
15B  8.3 9.1 1.11 (0.68,1.80) 0.688 1.40 (0.82,2.38) 0.220
16  5.9 6.6 1.11 (0.62,1.99) 0.755 1.00 (0.51,1.99) 0.992
19C  0.9 0.3 0.32 (0.03,3.09) 0.366 0.18 (0.03,1.06) 0.058
21  3.2 4.9 1.50 (0.71,3.15) 0.377 1.50 (0.71,3.15) 0.288
34  3.8 2.3 0.60 (0.25,1.42) 0.272 0.54 (0.22,1.36) 0.194
35B  4.7 4.9 1.03 (0.53,2.00) 1.000 0.88 (0.44,1.74) 0.713
NT  0.3 6.0 20.34 (2.75150.60) <0.001 19.82 (2.64,148.78) 0.004
RR, risk ratios; VT, vaccine types; NVT, non-vaccine types 6; NA, not applicable.
a p-Value from Fisher’s exact test.
b Adjusted for maternal age, household size, schooling, health centre, gender, exposure to smoke from cooking.
Table 3
Prevalence of pneumococcal carriage in mothers before (CSS1) and after (CSS2) introduction of PCV13 into the Gambian EPI programme.
Prevalence of carriage RR p-Valuea RRadjb p-Value
CSS1 (N = 331) CSS2 (N = 347)
Vaccine groups
PCV13 6.6 8.4 1.26 (0.74,2.14) 0.467 1.14 (0.65,2.01) 0.651
PCV7  2.7 2.6 0.95 (0.38,2.38) 1.000 0.85 (0.31,2.30) 0.744
PCV(13-7)VT 3.9 6.1 1.54 (0.78,3.03) 0.222 1.39 (0.67,2.86) 0.377
Pneumococcus 23.0 24.2 1.05 (0.80,1.38) 0.718 1.19 (0.88,1.60) 0.264
PCV13-VT
1  0.3 0 NA 0.488 NA NA
3  0 0.3 NA 1.000 NA NA
4  0.6 0.6 0.95 (0.13,6.74) 1.000 1.09 (0.09,13.70) 0.945
5  0 0.9 NA 0.249 NA NA
6A  1.8 2.0 1.11 (0.38,3.28) 1.000 1.25 (0.42,3.72) 0.685
6B  0 0 NA NA NA NA
7F  0 0 NA NA NA NA
9V  0 0 NA NA NA NA
14  0.6 0.3 0.48 (0.04,5.24) 0.616 0.36 (0.06,2.16) 0.266
18C  0.3 0.6 1.91 (0.17,20.98) 1.000 1.72 (0.05,60.93) 0.266
19A  1.8 3.2 1.75 (0.65,4.68) 0.328 1.36 (0.44,4.21) 0.589
19F  0.6 0.3 0.48 (0.04,5.24) 0.616 0.24 (0.02,3.07) 0.274
23F  0.6 0.9 1.43 (0.24,8.52) 1.000 1.23 (0.24,6.37) 0.805
NVT
10A  0.6 0.3 0.48 (0.04,5.24) 0.616 0.53 (0.05,5.12) 0.580
13  0.6 1.7 2.86 (0.58,14.09) 0.287 3.07 (0.60,15.62) 0.177
15B  0.6 1.7 2.86 (0.58,14.09) 0.287 2.72 (0.71,19.50) 0.120
16  2.4 0.6 0.24(0.05,1.12) 0.058 0.15 (0.03,0.72) 0.018
19C  1.2 0 NA 0.056 NA NA
21  0.9 0.9 0.95 (0.19,4.70) 1.000 0.52 (0.07,4.05) 0.535
34  1.2 1.2 0.95 (0.24,3.79) 1.000 0.75 (0.11,4.93) 0.761
35B  1.8 0.6 0.32 (0.06,1.57) 0.168 0.39 (0.08,1.87) 0.240
NT  0.3 1.4 4.77 (0.56,40.67) 0.217 3.93 (0.42,37.03) 0.231
RR, risk ratios; VT, vaccine types; NVT, non-vaccine types 6; NA, not applicable.
a p-Value from Fisher’s exact test.
b Adjusted for maternal age, household size, schooling, health centre.
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Table 4
Results of whole genome sequencing of non-typable isolates.
Isolate N CSS Mother/infant S. pneumoniae
% reads
S. pseudopneu-
moniae
%  reads
ST Nearest ST Capsular locus
top hit
Serotype speciﬁc
sequence detected
Ancestral capsular
type from
phylogeny
Conclusion VT or NVT
108887 1 Infant 78.08 0.71 3407 16F 16F 16F 16F not expressed NVT
105098  1 Mother 80.51 0.14 1778 34 34 34 34 not expressed NVT
104550  1 Mother 19.47 40.9 Unknown S. pseudopneumoniae —
201376 2 Infant 80.46 0.25 5521 10A 10A 10A 10A not expressed NVT
207381  2 Infant 82.09 0.4 Novel ST D 2052 20 20 Long branch,
inconclusive
20 not expressed NVT
206628  2 Infant 81.38 0.08 989 12F 12F/A/46 12F/A/46 12F/A/46 not expressed NVT
210240  2 Infant 80.96 0.08 989 12F 12F/A/46 12F/A/46 12F/A 46 not expressed NVT
210201  2 Infant 83.51 0.08 2447 14 14 14 14 not expressed VT
201867a 2 Infant 46.64 0.57 Novel ST B 4040 Classical NT 14 Capsule switch from 14 to
classically NT locus
VT
200954 2 Mother 81.22 0.25 Novel ST G 975 15B/C 15B/C 15B/C 15B/C not expressed NVT
206379  2 Infant 81.51 0.16 4033 15B/C 15B/C 15B/C 15B/C not expressed NVT
207139  2 Infant 76.55 0.57 3407 16F 16F 16F 16F not expressed NVT
210300  2 Infant 78.96 0.62 Novel ST F 3407 16F 16F 16F 16F not expressed NVT
210092  2 Infant 80.13 0.28 Novel ST E 847 19A 19A 19A 19A not expressed VT
210344  2 Infant 79.93 0.19 Unknown 7661 19B 19B 19B not expressed NVT
206438  2 Infant 81.8 0.1 202 19A 19A Long branch,
inconclusive
19A not expressed VT
208478  2 Infant 81.95 0.17 4033 19F 19F 19F/15B/C 19F not expressed VT
202731  2 Infant 81.26 0.08 Novel ST C 6712 28A/F 28A/F 28A/F not expressed NVT
201297  2 Mother 81.95 0.34 5734 6A/B/C/D 6A/B/C/D 6A 6A not expressed VT
201794  2 Infant 78.82 0.8 Novel ST A 71 38 (low match
35%)
Long branch,
inconclusive
cps locus lost —
201398  2 Mother 76.17 1.3 Novel ST H 3582 Classical NT Long branch,
inconclusive
Capsule switch to
classically NT locus
—
201843 2 Infant 77.28 1.11 4040 Classical NT 14 Capsule switch from 14 to
classically NT locus
VT
205597 2 Infant 75.37 0.96 Novel ST B 4040 Classical NT 14 Capsule switch from 14 to
classically NT locus
VT
206158 2 Mother 78.28 0.89 Novel ST B 4040 Classical NT 14 Capsule switch from 14 to
classically NT locus
VT
201133 2 Infant 64.27 3.02 344 Classical NT Classical NT Classical NT –
202601  2 Mother 65.69 2.64 448 Classical NT Classical NT Classical NT –
208136  2 Infant 66.12 2.67 448 Classical NT Classical NT Classical NT –
201017  2 Infant 17.54 43.18 Unknown S. pseudopneumoniae –
209574  2 Infant 20.05 40.36 Unknown S. pseudopneumoniae –
CSS, cross-sectional; VT, vaccine-types; NVT, non-vaccine types; NT, non-typable; ST, sequence type.
a Sample contaminated with unclassiﬁed organism, pneumococcal coverage sufﬁcient for analysis and conclusions.
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Fig. 1. Phylogenetic context of non-typable isolates. (i) Outer ring: non-typable isolates from this study highlighted (light green). (ii) Middle ring: major lineages, S. pseu-
dopneumoniae (purple), Classical non-typable (green), Typically encapsulated (yellow). (iii) Inner ring and branch colouring: clusters of serotypes giving context to study
isolates. (iv) Leaf labels: Serotype of isolate giving context to study isolates or study ID of non-typable study isolates.
of these isolates were S. pseudopneumoniae, 3 were of the classical
non-typable lineage (10.7%) and the others [22 out of 28 (78.6%)]
were of the typically encapsulated pneumococcal lineage and had
lost their ability to express capsule through one of three different
mechanisms (Fig. 1). Sixteen of these appear to have a standard
cps locus but a capsule was not phenotypically detected, one iso-
late only had remnants of the cps locus whilst the remaining 5
had acquired a locus typically found in classically non-typable iso-
lates. These latter isolates were closely related and cluster in the
phylogeny predominantly within a serotype 14 lineage (Fig. 1 and
Table 4), accounting for 4 out of the 5 NT isolates from a serotype
14 background.
Among the 16 infants carrying non-typable isolates that were
not classical, 7 (43.7%) were of VT lineage. This is almost double
the proportion of VT carriers among infant carriers in CSS2 (23.4%)
(p = 0.076).
4. Discussion
The Gambia was  the second African country to introduce PCV7
into the EPI. For two years children received PCV7, but soon after
PCV13 was licensed, the earlier vaccine was replaced by the higher
valency formulation. To the best of our knowledge, the impact of
replacing PCV7 with PCV13 within EPI programmes has not yet
been reported in the African continent. Our study showed that over-
all prevalence of pneumococcal nasopharyngeal carriage among
infants was  comparable between PCV7 and PCV13 vaccinated chil-
dren but that the distribution of serotypes differed between groups,
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with a signiﬁcant decrease of the additional serotypes included
in PCV13 [PCV(13-7)-VT]. We  also observed an increase on non-
typables isolates in CSS2, mainly of serotypes that had lost their
capsule, most likely in response to vaccine pressure. No signiﬁcant
increase of NVT between CSS was observed.
In PCV13 vaccinated infants, the prevalence of PCV(13-7)-VT
almost halved. Most of the difference was attributable to a decrease
in the prevalence of serotype 6A, from 15.3% in CSS1 to 5.7% in CSS2.
Even with this decrease, the prevalence of serotype 6A was  still 6%
in CSS2 and represented 42% of all PCV(13-7)-VT serotypes. These
results, along with previous results in The Gambia, suggest that
cross-protection between 6A and 6B was probably very low, if any
[7]. The observed decrease of serotype 19A was not statistically
signiﬁcant; it was the most prevalent PCV(13-7)-VT in CSS2, and
accounted for 47% of all PCV(13-7)-VT serotypes.
A notable difference between CSS1 and CSS2 was  the increase
in non-typable isolates in CSS2 (adjusted RR among infants 19.82).
Prevalence of non-typable isolates in CSS2 (6% in infants) was
higher than in CSS1 and also higher than in previous studies
conducted in The Gambia [7,33]. The WGS  analysis of these non-
typables pneumococci showed that most of them were not among
the classical non-typable lineage, but instead, represented seroty-
pable isolates that did not express a capsule. Capsule loss is not a
rare event in the pneumococcus [34]. However, because the preva-
lence of VT lineages among isolates with loss of capsule expression
was higher than the overall prevalence of VT isolates among car-
riers, this loss of capsule expression may  be, at least partly, due to
a response of the pneumococcal population to vaccine selection
pressure. Although this analysis was not statistically signiﬁcant
the study was not powered for this endpoint. If our ﬁndings are
true, we may  expect an increase in carriage of non-typable pneu-
mococcus. Further monitoring is warranted to determine whether
non-typable serotypes carried in the nasopharynx are associated
with increase in disease.
Our results differ slightly from similar studies recently con-
ducted in other continents. In Israel, investigators observed a
moderate decrease of overall carriage [35] contrasting with our
results where no effect on overall pneumococcal carriage was
observed in either vaccinated infants or their mothers. In the US,
the prevalence of carriage remained stable after PCV13 introduc-
tion but a moderate increase of NVT, mainly due to serotype 35B,
was observed [36]. In Italy, a greater reduction of serotype 19A was
observed in children vaccinated with PCV13 [37].
As young children are the major reservoir of S. pneumoniae, the
impact of the vaccine on carriage in this group plays a signiﬁcant
role in determining the impact of the vaccine on the community as
a whole [7]. We  included mothers in our analysis as, among adults,
they are likely to beneﬁt soonest from the indirect effect of the
vaccine. However, one year after vaccine introduction we did not
ﬁnd a reduction in PCV13 serotypes among mothers whose chil-
dren had been vaccinated with PCV13. This emphasises the fact
that the indirect protective effect of PCVs may  take several years
to reach their maximum impact, and is consistent with the predic-
tion of a recent mathematical model that population-wide serotype
replacement in The Gambia will occur over a ﬁve year period
[38].
Unfortunately, because of the study design, it is impossible to
account for increasing herd effect after PCV7 introduction. Some
of the differences among infants in CSS1 and CSS2, such as the
decrease in PCV7-VT, could be related to the time since PCV intro-
duction rather than the effect of the new vaccine. However, the
decrease of PCV(13-7)VT (which includes only the serotypes from
PCV13 that are not included in PCV7) in CSS2 cannot be explained
by the longer time since the introduction of PCV7 and therefore the
most likely explanation is the introduction of the new formulation.
Our ﬁndings are in line with data from a RCT conducted in Israel
comparing PCV7 versus PCV13 [20]. Secular trends, however, can
occur in a before and after design.
Despite the challenges considered above, our data show that
PCV13 resulted in lower carriage of PCV(13-7)VT with the strongest
effect on an important serotype, 6A. These ﬁndings represent the
ﬁrst evidence of the impact of PCV13 in nasopharyngeal colo-
nization in Africa, which may  serve as a predictor of vaccine
effectiveness through both direct and indirect effects. In addition,
our results suggest that non-typable isolates will probably become
more common in Africa with increasing deployment of PCV13.
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